Allergan settles Forest Pharmaceuticals sales, marketing practices suit for $38M: 3 things to know

Dublin, Ireland-based Allergan settled its case with the federal government over the sales and marketing practices of three Forest Pharmaceuticals drugs Savella, Namenda and Bystolic.

Advertisement

Here’s what you should know.

1. Allergan is paying the federal government $38 million and settling all claims related to the three drugs. Under a different leadership team, Forest allegedly made payments to physicians for conducting speaking programs,

2. The settlement will not affect Allergan’s ongoing business.

3. Allergan’s Global Vice President Jonathon Kellerman said that Allergan’s compliance organization is making sure its policies stay “best-in-class.”

More articles on health:
Albert and Mary Lasker Foundation honors 3 researchers for GI contributions
DoD honors Dr. Brent Lacey for hepatitis C program & more — 4 GI physicians in the headlines
Providers trying out disposable scopes in wake of superbug outbreaks

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC News

Advertisement

Comments are closed.